Azura公司实验中的新药AZR-MD-001于2022年末完成了二期临床测试,预计于今年三月开启第三轮临床测试。一直以来对于MDG的治疗都是间接药物治疗或者物理治疗,而AZR则是借助去角质剂(Keratolytics)的化学性质融化睑板腺油脂,并在此基础上增加油脂的分泌量。以下内容转自Azura官网:Azura 的主要临床阶段候选药物 AZR-MD-001...
Azura is currently conducting a multi-center, double-masked, vehicle-controlled Phase 2b study that will evaluate the safety and efficacy of AZR-MD-001 in patients with MGD. Primary endpoints will include patient-reported symptoms as measured by the Ocular Surf...